Integration of Toyama Chemical and FUJIFILM RI Pharma
First written in FY2018. 2 of 5 entries say "Achieved", first in FY2019-Q3. Latest entry: FY2022.
No other company in this theme has enough history to compare yet.
- FY2022AchievedAnnual report
「On 28 March 2022, we transferred the radiopharmaceutical business of FUJIFILM Toyama Chemical Co., Ltd. to PeptiDream Inc.」
The transfer of the radiopharmaceutical business established after the integration of Toyama Chemical and FUJIFILM RI Pharma was completed on 28 March 2022. - FY2022-Q2SoftenedAnnual report
「In September 2021, as part of efforts to optimise the business portfolio in the life sciences field, we decided to transfer the radiopharmaceutical business of FUJIFILM Toyama Chemical Co., Ltd. to PeptiDream Inc.」
The company announced plans to transfer the radiopharmaceutical business established through the integration of Toyama Chemical and FUJIFILM RI Pharma, narrowing and reorganising the scope of the post-integration business. The transfer was scheduled for March 2022. - FY2019-Q3AchievedAnnual report
「On 1 October 2018, we integrated Toyama Chemical Co., Ltd., which conducts research, development, manufacturing, and sales of small-molecule pharmaceuticals, with FUJIFILM RI Pharma Co., Ltd., which conducts research, development, manufacturing, and sales of radiopharmaceuticals. Under the new company name FUJIFILM Toyama Chemical Co., Ltd., we will improve operational efficiency and accelerate the development of new therapeutic and diagnostic drugs.」
The integration of Toyama Chemical and FUJIFILM RI Pharma was completed on 1 October 2018, moving the new company toward greater operational efficiency and accelerated development of therapeutic and diagnostic drugs. - FY2019-Q1AdvancedAnnual report
「In preparation for launching the new company, on 31 July 2018 we acquired all shares of Toyama Chemical held by Taisho Pharmaceutical Holdings Co., Ltd. and made Toyama Chemical our wholly owned subsidiary.」
Regarding the integration plan for Toyama Chemical and FUJIFILM RI Pharma, progress had reached the acquisition of all shares of Toyama Chemical and its conversion into a wholly owned subsidiary on 31 July 2018. - FY2018First statedAnnual report
「At a meeting of the Board of Directors held on 10 May 2018, we decided to integrate Toyama Chemical Co., Ltd., which conducts research, development, manufacturing, and sales of small-molecule pharmaceuticals, with FUJIFILM RI Pharma Co., Ltd., which conducts research, development, manufacturing, and sales of radiopharmaceuticals, effective 1 October 2018, and launch the combined company as FUJIFILM Toyama Chemical Co., Ltd., in order to accelerate the development of new diagnostic and therapeutic drugs.」
The company first disclosed a restructuring plan to integrate the small-molecule pharmaceutical and radiopharmaceutical businesses effective 1 October 2018 and accelerate the development of new diagnostic and therapeutic drugs.